retatrutide triple agonist glp-1 gip glucagon phase 3 2025 Retatrutide, a (GLP1, GIP, glucagon), just released 2 trial results demonstrating 25% weight loss in half of people with #obesity. This amount of weight loss has not been accomplished Retatrutide (Eli Lilly's triple GLP-1/GIP/Glucagon
Description
Randomized Clinical Trial Diabetes Care
10.1016/j.neuropharm.2014.04.007 [DOI] [PubMed] [Google Scholar] 100.Cui SS, Feng XB, Zhang BH, Xia ZY, Zhan LY
Ricks said supply for Zepbound isnt a concern for Lilly, regardless of whether people get it from a local pharmacy or LillyDirect
Prepared by the editors of Harvard Health Publishing in consultation with Chika V
These heterogeneous responses are modulated by multiple factors, including tumor classification, study methodology, treatment duration, and patient-specific parameters (Table 1)
Some patients maintain a portion of their weight loss after stopping, especially those who have made significant lifestyle changes
